Stereotaxis Inc. Common Stock (STXS)
Stock · AMEX · Health Care
$1.02as of 10/16/2026
Price chart
Active signals
STXS Signal Track Record
How signals performed across all stocks →What STXS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | -6.1% | 46% | July 16, 2026 |
| Bollinger Band Breakout | 29 | -3.7% | 31% | May 28, 2026 |
| Bollinger Band Breakdown | 16 | -0.5% | 44% | October 1, 2026 |
| 200-Day Moving Average TouchActive now | 15 | -2.8% | 40% | January 28, 2026 |
| Any 20-session window (baseline) | -0.5% | 48% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About STXS
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambe…
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Employees
- 131
- Website
- www.stereotaxis.com/
Fundamentals
- 1-day range
- $1$1.07
- Market cap
- $133.19M
- P/E (trailing)
- —
- P/E (forward)
- -6.52
- EPS (trailing)
- $-0.23
- Dividend yield
- —
- Beta
- 1.39
- Avg. volume
- 665.1K
How Stereotaxis Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 12, 2026 · via SEC EDGAR / Finnhub
Forecasts
3 analyst ratings
Stereotaxis Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- STXSStereotaxis Inc. Common Stock$1.01▼ 3.81%Market cap $133.19MP/E —$1.02$3.2
- VANIVivani Medical Inc. Common Stock (DE)$1.12▼ 2.61%Market cap $117.28MP/E —$0.9227$1.92
- HSDTSolana Company Class A Common Stock (DE)$2.24▼ 4.68%Market cap $98.09MP/E —$1.19$16.81
- HYPRHyperfine Inc. Class A Common Stock$0.755▼ 3.21%Market cap $97.48MP/E —$0.7536$2.22
- OMOutset Medical Inc. Common Stock$3.94▼ 3.43%Market cap $96.39MP/E —$2.84$15.94
- NRXSNeuraxis Inc. Common Stock$7.7▼ 0.52%Market cap $86.47MP/E —$2.21$9.33
- STEXStreamex Corp. Common Stock$0.374▼ 8.33%Market cap $75.35MP/E —$0.3876$6.5
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| STXS Stereotaxis Inc. Common Stock | $133.19M | — | $1.01 | ▼ 3.81% | $1.02$3.2 |
| VANI Vivani Medical Inc. Common Stock (DE) | $117.28M | — | $1.12 | ▼ 2.61% | $0.9227$1.92 |
| HSDT Solana Company Class A Common Stock (DE) | $98.09M | — | $2.24 | ▼ 4.68% | $1.19$16.81 |
| HYPR Hyperfine Inc. Class A Common Stock | $97.48M | — | $0.755 | ▼ 3.21% | $0.7536$2.22 |
| OM Outset Medical Inc. Common Stock | $96.39M | — | $3.94 | ▼ 3.43% | $2.84$15.94 |
| NRXS Neuraxis Inc. Common Stock | $86.47M | — | $7.7 | ▼ 0.52% | $2.21$9.33 |
| STEX Streamex Corp. Common Stock | $75.35M | — | $0.374 | ▼ 8.33% | $0.3876$6.5 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- SHAMIR NACHUM · July 1, 2026 · Grant43.1K
- Benfer David · July 1, 2026 · Grant43.1K
- Levin Ross B · July 1, 2026 · Grant43.1K
- Fischel Nathan · July 1, 2026 · Grant43.1K
- Myriam Curet · July 1, 2026 · Grant43.1K
- Arun Swarup Menawat · July 1, 2026 · Grant43.1K
Institutional Ownership
March 31, 2026
- Total shares held
- 41.59M
- Total value held
- $76.30M
- Institutional holders
- 111
- Unknown13.68M
- Unknown4.35M
- Unknown3.96M
- Unknown3.00M
- Unknown2.88M
- Unknown1.68M
- Unknown1.59M
- Unknown1.23M
- Unknown1.09M
- Unknown957.8K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
No recent news for STXS
There are no new developments for Stereotaxis Inc. in the past week. The company continues to trade near its 12‑month low, with an RSI of 22.8 indicating oversold conditions. The 52‑week range remains $1.09 to $3.59, and analysts maintain a target of $3.00.
No recent news for STXS. There are no new developments for Stereotaxis Inc. in the past week. The company continues to trade near its 12‑month low, with an RSI of 22.8 indicating oversold conditions. The 52‑week range remains $1.09 to $3.59, and analysts maintain a target of $3.00.